<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868126</url>
  </required_header>
  <id_info>
    <org_study_id>33-002</org_study_id>
    <nct_id>NCT01868126</nct_id>
  </id_info>
  <brief_title>Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of four concentrations of
      DE-117 ophthalmic solution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 28-day randomized, observer-masked, placebo-and active-controlled, parallel-group,
      multi-center, study investigating the safety and efficacy of four concentrations of DE-117
      ophthalmic solution when compared to latanoprost (0.005% latanoprost) and placebo (vehicle of
      DE-117) in subjects with primary open-angle glaucoma or ocular hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (mmHg)</measure>
    <time_frame>Day 1, Day 8, Day 15 and Day 29</time_frame>
    <description>Intraocular pressure (mmHg) measurements will be collected at each visit using Goldmann applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 1, Day 8, Day 15 and Day 29</time_frame>
    <description>Adverse events will be assessed at each visit to evaluate safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular signs and symptoms</measure>
    <time_frame>Day 1, Day 8, Day 15 and Day 29</time_frame>
    <description>Ocular symptoms and ocular signs will be collected at each visit using slit lamp biomicroscopy, dilated ophthalmoscopy, gonioscopy, automated perimetry visual field testing, corrected visual acuity and pachymetry</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Open-angle Glaucoma or Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Group 1: DE-117 ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop DE-117 Low Dose in each eye daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: DE-117 ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop DE-117 Low Middle Dose in each eye daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: DE-117 ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop DE-117 High Middle Dose in each eye daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: DE-117 ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop DE-117 High Dose in each eye daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost ophthalmic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One drop latanoprost 0.005% in each eye daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (vehicle of DE-117) ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop DE-117 vehicle in each eye once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 ophthalmic solution</intervention_name>
    <arm_group_label>Group 1: DE-117 ophthalmic solution</arm_group_label>
    <arm_group_label>Group 2: DE-117 ophthalmic solution</arm_group_label>
    <arm_group_label>Group 3: DE-117 ophthalmic solution</arm_group_label>
    <arm_group_label>Group 4: DE-117 ophthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost ophthalmic solution</intervention_name>
    <arm_group_label>latanoprost ophthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo (vehicle of DE-117) ophthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Current diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes

          -  Qualifying intraocular pressure in at least one eye at Baseline

          -  Qualifying corrected ETDRS visual acuity in each eye

          -  Qualifying central cornea thickness in each eye

        Main Exclusion Criteria:

          -  Closed/barely open anterior chamber angle or a history of acute angle closure in
             either eye

          -  Diagnosis of primary open-angle glaucoma or ocular hypertension due to etiology known
             to be non-responsive to conventional drug therapy

          -  Evidence of advanced glaucoma, visual field defect or progressive visual field loss
             that that do not meet the study criteria

          -  History of ocular surgery specifically intended to lower IOP

          -  History of any ocular or systemic abnormality or condition that may put the subject at
             significant risk, may confound study results, or may interfere significantly with the
             subject's participation in the study

          -  Intended or current use of any ocular medications other than study medications during
             the study

          -  Use of contact lenses within one week prior to Baseline (Day 1) until end of treatment

          -  Known allergy or sensitivity to any components of the study medications

          -  Use of steroids (systemic) within 30 days prior to Visit 1 (Screening)

          -  Anticipate the need to initiate or modify an existing chronic therapy that could
             substantially affect IOP or the study outcomes during the study period

          -  Females who are pregnant, nursing or planning a pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Santen</keyword>
  <keyword>Eye</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

